Advertisement

Radiotherapy and Second Generation Drugs

  • Michael Geier
  • Nicolaus Andratschke
Chapter
Part of the Medical Radiology book series (MEDRAD)

Abstract

Unsatisfactory outcomes with radiotherapy alone and the advent of very potent and possibly radiation enhancing drugs, especially platinum compounds and vinkaalkaloids, prompted the preclinical and clinical investigation of combinded radiochemotherapy protocols with second generation chemotherapeutic drugs as a definitive treatment in inoperable NSCLC. Not for all substances used unequivocal experimental evidence for a true radiosensitizing effect could be demonstrated. Instead, the effects may result from independent additive cytotoxicity crucial for sterilizing clonogenic tumor cells surviving radiotherapy and a different non-overlapping toxicity profile. This chapter summarizes the preclinical data and early clinical evidence for the rational of combining second generation drugs with radiotherapy in advanced stage NSCLC.

Keywords

Induction Chemotherapy Concurrent Chemoradiation Accelerate Radiotherapy Advanced Stage NSCLC Inoperable NSCLC 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Albain KS, Crowley JJ, Turrisi AT 3rd, Gandara DR, Farrar WB, Clark JI, Beasley KR, Livingston RB (2002) Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 20:3454–3460 PubMedCrossRefGoogle Scholar
  2. Ardizzoni A, Grossi F, Scolaro T, Giudici S, Foppiano F, Boni L, Tixi L, Cosso M, Mereu C, Ratto GB, Vitale V, Rosso R (1999) Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer. Br J Cancer 81:310–315. doi: 10.1038/sj.bjc.6690693 PubMedCrossRefGoogle Scholar
  3. Atagi S, Kawahara M, Hosoe S, Ogawara M, Kawaguchi T, Okishio K, Naka N, Sunami T, Mitsuoka S, Akira M (2002) A phase II study of continuous concurrent thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer. Lung Cancer 36:105–111. PII:S0169500201004603PubMedCrossRefGoogle Scholar
  4. Bardet E, Riviere A, Charloux A, Spaeth D, Ducolone A, Le Groumellec A, Pellae-Cosset B, Henry-Amar M, Douillard JY (1997) A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced non-small-cell lung cancer: final analysis. Int J Radiat Oncol Biol Phys 38:163–168. PII:S036030169700254XPubMedCrossRefGoogle Scholar
  5. Binaschi M, Zunino F, Capranico G (1995) Mechanism of action of DNA topoisomerase inhibitors. Stem Cells 13:369–379. doi: 10.1002/stem.5530130408 PubMedCrossRefGoogle Scholar
  6. Blanke C, DeVore R, Shyr Y, Epstein B, Murray M, Hande K, Stewart S, Johnson D (1997) A pilot study of protracted low dose cisplatin and etoposide with concurrent thoracic radiotherapy in unresectable stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 37:111–116. PII:S0360301696004786PubMedCrossRefGoogle Scholar
  7. Boven E, Tierie AH, Stam J, Pinedo HM (1988) Combined radiation therapy and daily low-dose cisplatin for inoperable, locally advanced non-small-cell lung cancer: results of a phase II trial. Semin Oncol 15:18–19PubMedGoogle Scholar
  8. Byhardt RW, Scott CB, Ettinger DS, Curran WJ, Doggett RL, Coughlin C, Scarantino C, Rotman M, Emami B (1995) Concurrent hyperfractionated irradiation and chemotherapy for unresectable non-small-cell lung cancer. Results of radiation therapy oncology group 90–15. Cancer 75:2337–2344PubMedCrossRefGoogle Scholar
  9. Chen AY, Okunieff P, Pommier Y, Mitchell JB (1997) Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res 57:1529–1536PubMedGoogle Scholar
  10. Dewit L (1987) Combined treatment of radiation and cis-diamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys 13:403–426PubMedCrossRefGoogle Scholar
  11. Douple EB, Richmond RC (1978) Platinum complexes as radiosensitizers of hypoxic mammalian cells. Br J Cancer Suppl 3:98–102PubMedGoogle Scholar
  12. Fleming RA (1997) An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 17:146S–154SPubMedGoogle Scholar
  13. Furuse K, Kubota K, Kawahara M, Kodama N, Ogawara M, Akira M, Nakajima S, Takada M, Kusunoki Y, Negoro S et al (1995) Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka lung cancer study group. J Clin Oncol 13:869–875PubMedGoogle Scholar
  14. Grau C, Overgaard J (1991) Radiosensitizing and cytotoxic properties of mitomycin C in a C3H mouse mammary carcinoma in vivo. Int J Radiat Oncol Biol Phys 20:265–269PubMedCrossRefGoogle Scholar
  15. Hazuka MB, Crowley JJ, Bunn PA Jr, O’Rourke M, Braun TJ, Livingston RB (1994) Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology group study. J Clin Oncol 12:1814–1820PubMedGoogle Scholar
  16. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Milisavljevic S (1998) Concurrent radiochemotherapy for patients with stage III non-small-cell lung cancer (NSCLC): long-term results of a phase II study. Int J Radiat Oncol Biol Phys 42:1091–1096. PII:S0360-3016(98)00283-1PubMedCrossRefGoogle Scholar
  17. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253–265. doi: 10.1038/nrc131710.1038/nrc1317 PubMedCrossRefGoogle Scholar
  18. Jeremic B, Shibamoto Y, Milicic B, Milisavljevic S, Nikolic N, Dagovic A, Aleksandrovic J, Radosavljevic-Asic G (1999) A phase II study of concurrent accelerated hyperfractionated radiotherapy and carboplatin/oral etoposide for elderly patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 44:343–348. PII:S0360-3016(99)00006-1PubMedCrossRefGoogle Scholar
  19. Kalemkerian GP, Belzer K, Wozniak AJ, Gaspar LE, Valdivieso M, Kraut MJ (1999) Phase I trial of concurrent thoracic radiation and continuous infusion cisplatin and etoposide in stage III non-small-cell lung cancer. Lung Cancer 25:175–182. PII:S0169500299000604PubMedCrossRefGoogle Scholar
  20. Kelly K, Hazuka M, Pan Z, Murphy J, Caskey J, Leonard C, Bunn PA Jr (1998) A phase I study of daily carboplatin and simultaneous accelerated, hyperfractionated chest irradiation in patients with regionally inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 40:559–567. PII:S0360301697007694PubMedCrossRefGoogle Scholar
  21. Komaki R, Scott C, Ettinger D, Lee JS, Fossella FV, Curran W, Evans RF, Rubin P, Byhardt RW (1997) Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group (RTOG) 92–04. Int J Radiat Oncol Biol Phys 38:149–155. PII:S0360-3016(97)00251-4PubMedCrossRefGoogle Scholar
  22. Komaki R, Seiferheld W, Ettinger D, Lee JS, Movsas B, Sause W (2002) Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92–04. Int J Radiat Oncol Biol Phys 53:548–557. PII:S0360301602027931PubMedCrossRefGoogle Scholar
  23. Kubota K, Tamura T, Fukuoka M, Furuse K, Ikegami H, Ariyoshi Y, Kurita Y, Saijo N (2000) Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: long-term follow-up results. Japan clinical oncology group protocol 8902. Ann Oncol 11:445–450PubMedCrossRefGoogle Scholar
  24. Latz D, Weber KJ (2002) Transient DNA double-strand breakage in 4-hydroperoxyifosfamide-treated mammalian cells in vitro does not interact with the rejoining of radiation-induced double-strand breaks. Strahlenther Onkol 178:269–274PubMedCrossRefGoogle Scholar
  25. Latz D, Schulze T, Manegold C, Schraube P, Flentje M, Weber KJ (1998) Combined effects of ionizing radiation and 4-hydroperoxyfosfamide in vitro. Radiother Oncol 46:279–283. PII:S0167814097001941PubMedCrossRefGoogle Scholar
  26. Lau DH, Crowley JJ, Gandara DR, Hazuka MB, Albain KS, Leigh B, Fletcher WS, Lanier KS, Keiser WL, Livingston RB (1998) Southwest oncology group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol 16:3078–3081PubMedGoogle Scholar
  27. Le Pechoux C, Arriagada R, Le Chevalier T, Bretel JJ, Cosset BP, Ruffie P, Baldeyrou P, Grunenwald D (1996) Concurrent cisplatin-vindesine and hyperfractionated thoracic radiotherapy in locally advanced non-small-cell-lung cancer. Int J Radiat Oncol Biol Phys 35:519–525. PII:0360301696001484PubMedGoogle Scholar
  28. Lee JS, Scott C, Komaki R, Fossella FV, Dundas GS, McDonald S, Byhardt RW, Curran WJ Jr (1996) Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91–06. J Clin Oncol 14:1055–1064PubMedGoogle Scholar
  29. Lee JS, Komaki R, Fossella FV, Glisson BS, Hong WK, Cox JD (1998) A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer: a 5 year follow-up report. Int J Radiat Oncol Biol Phys 42:479–486. PII:S0360-3016(98)00247-8PubMedCrossRefGoogle Scholar
  30. Lee SW, Choi EK, Lee JS, Lee SD, Suh C, Kim SW, Kim WS, Ahn SD, Yi BY, Kim JH, Noh YJ, Kim SS, Koh Y, Kim DS, Kim WD (2003) Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 56:996–1004. PII:S0360301603001275PubMedCrossRefGoogle Scholar
  31. Mirimanoff RO, Moro D, Bolla M, Michel G, Brambilla C, Mermillod B, Miralbell R, Alberto P (1998) Alternating radiotherapy and chemotherapy for inoperable Stage III non-small-cell lung cancer: long-term results of two Phase II GOTHA trials. Groupe d’Oncologie Thoracique Alpine. Int J Radiat Oncol Biol Phys 42:487–494. PII:S0360301698002466CrossRefGoogle Scholar
  32. Palazzi M, Morrica B, Montanaro P, Cerizza L, Leoni M (1996) Hyperfractionated radiotherapy and concomitant cisplatin in stage III non-small cell lung cancer: a phase II study by the AIRO-Lombardia Cooperative Group. Lung Cancer 15:85–91. PII:0169500296005739PubMedCrossRefGoogle Scholar
  33. Planting A, Helle P, Drings P, Dalesio O, Kirkpatrick A, McVie G, Giaccone G (1996) A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer. An EORTC Lung Cancer Cooperative Group trial. Ann Oncol 7:139–144PubMedCrossRefGoogle Scholar
  34. Pottgen C, Eberhardt W, Bildat S, Stuben G, Stamatis G, Hillejan L, Sohrab S, Teschler H, Seeber S, Sack H, Stuschke M (2002) Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial. Ann Oncol 13:403–411PubMedCrossRefGoogle Scholar
  35. Pujol JL, Lafontaine T, Quantin X, Reme-Saumon M, Cupissol D, Khial F, Michel FB (1999) Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer. Chest 115:144–150 PubMedCrossRefGoogle Scholar
  36. Sarihan S, Darendeliler E, Kizir A, Tuncel N, Oral EN, Karadeniz A, Bilge N (1998) A phase II trial, feasibility of combination of daily cisplatinum and accelerated radiotherapy via concomitant boost in stage III non-small cell lung cancer. Lung Cancer 20:37–46. PII:S0169500298000038PubMedCrossRefGoogle Scholar
  37. Scagliotti GV, Ricardi U, Crino L, Maranzano E, De Marinis F, Morandi MG, Meacci L, Marangolo M, Emiliani E, Rosti G, Figoli F, Bolzicco G, Masiero P, Gentile A, Tonato M (1996) Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer. Cancer Chemother Pharmacol 38:561–565PubMedCrossRefGoogle Scholar
  38. Sekine I, Nishiwaki Y, Ogino T, Yokoyama A, Saito M, Mori K, Tsukiyama I, Tsuchiya S, Hayakawa K, Yoshimura K, Ishizuka N, Saijo N (2002) Phase II study of twice-daily high-dose thoracic radiotherapy alternating with cisplatin and vindesine for unresectable stage III non-small-cell lung cancer: Japan Clinical Oncology Group Study 9306. J Clin Oncol 20:797–803PubMedCrossRefGoogle Scholar
  39. Sui M, Fan W (2005) Combination of gamma-radiation antagonizes the cytotoxic effects of vincristine and vinblastine on both mitotic arrest and apoptosis. Int J Radiat Oncol Biol Phys 61:1151–1158. PII:S0360-3016(04)03144-XPubMedCrossRefGoogle Scholar
  40. Thomas P, Kleisbauer JP, Robinet G, Clavier J, Poirier R, Vernenegre A, Bonnaud F, Taytard A, Paillotin D, Pommier De Santi P, Barriere JR, Pignon T (1997) Carboplatin as radiosensitizer in non-small cell lung cancer after cisplatin containing chemotherapy. A phase I study of a groupe francais de pneumo-cancerologie (G.F.P.C.). Lung Cancer 18:71–81. PII:S0169-5002(97)00047-0 PubMedCrossRefGoogle Scholar
  41. Tsuchiya S, Ohe Y, Sugiura T, Fuwa N, Kitamoto Y, Mori K, Kobayashi H, Nakata K, Sawa T, Hirai K, Etoh T, Saka H, Saito A, Fukuda H, Ishizuka N, Saijo N (2001) Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601). Jpn J Clin Oncol 31:488–494PubMedCrossRefGoogle Scholar
  42. Uitterhoeve AL, Belderbos JS, Koolen MG, van der Vaart PJ, Rodrigus PT, Benraadt J, Koning CC, Gonzalez Gonzalez D, Bartelink H (2000) Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer. Eur J Cancer 36:592–600. PII:S0959804999003159PubMedCrossRefGoogle Scholar
  43. Van Belle S, Fortan L, De Smet M, De Neve W, Van der Elst J, Storme G (1994) Interaction between vinblastine and ionizing radiation in the mouse MO4 fibrosarcoma in vivo. Anticancer Res 14:1043–1048 PubMedGoogle Scholar
  44. Van den Brande P, De Ruysscher D, Vansteenkiste J, Spaas P, Specenier P, Demedts M (1998) Sequential treatment with vindesine-ifosfamide-platinum (VIP) chemotherapy followed by platinum sensitized radiotherapy in stage IIIB non-small cell lung cancer: a phase II trial. Lung Cancer 22:45–53. PII:S0169-5002(98)00071-3PubMedCrossRefGoogle Scholar
  45. van Harskamp G, Boven E, Vermorken JB, van Deutekom H, Stam J, Njo KH, Karim AB, Tierie AH, Golding RP, Pinedo HM (1987) Phase II trial of combined radiotherapy and daily low-dose cisplatin for inoperable, locally advanced non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 13:1735–1738PubMedCrossRefGoogle Scholar
  46. Verweij J, Pinedo HM (1990) Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs 1:5–13PubMedCrossRefGoogle Scholar
  47. Ziegler W, Kopp JM (1987) The effect of combined treatment of HeLa cells with cisplatin and irradiation upon survival and recovery from radiation damage. Radiother Oncol 8:71–78PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  1. 1.Department of Radiation OncologyTechnical University of MunichMunichGermany

Personalised recommendations